A microglial PET study identified extensive binding suggestive of increased microglial activation in CBD [65], but in the present study, the lack of microglial activation in most regions in FTLD-CBD cases suggests there may be dysfunction of this phenotype in areas of particularly high tau burden by the end stage of disease. This evidence concerns the gene MAPT and red-green color blindness.